{"id":"rivaroxaban-and-aspirin-80","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Bruising"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban is a direct Factor Xa inhibitor that blocks a key step in the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation. Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet aggregation. Together, they provide complementary anticoagulant and antiplatelet mechanisms for thromboprophylaxis.","oneSentence":"This combination uses rivaroxaban to inhibit Factor Xa in the coagulation cascade while aspirin inhibits platelet aggregation, providing dual anticoagulant and antiplatelet effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:29.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in acute coronary syndrome or cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT04273516","phase":"PHASE2, PHASE3","title":"Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2020-08-22","conditions":"Stroke, Prevention","enrollment":42},{"nctId":"NCT06019741","phase":"PHASE4","title":"Rivaroxaban Post Coronary Bypass Surgery","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2021-02-01","conditions":"Post Coronary Bypass Surgery Patients","enrollment":234},{"nctId":"NCT05210725","phase":"PHASE4","title":"Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-03-01","conditions":"Coronary Artery Disease","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rivaroxaban and aspirin 80","genericName":"Rivaroxaban and aspirin 80","companyName":"Shiraz University of Medical Sciences","companyId":"shiraz-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses rivaroxaban to inhibit Factor Xa in the coagulation cascade while aspirin inhibits platelet aggregation, providing dual anticoagulant and antiplatelet effects. Used for Thromboprophylaxis in acute coronary syndrome or cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}